• Our Way
  • About CANCER FUND I
    • PORTFOLIO
      • Reglagene
      • Metabolytix
    • Capital
  • Invest
    • CANCER FUND I
  • Our Team
  • Our Community
    • Virtual Screening Committee
    • The Lowdown on Cancer Blog
    • Celebrations
      • Celebrate Your Cancer Hero
    • Community Stories
      • Share Your Story
    • Subscribe
  • FAQ

Saving Second Base: Recapping Our Second Innovators

by jeff | Oct 15, 2021 | Breast Cancer, Innovators

Over the past weeks, we’ve introduced four additional innovators at the forefront of cancer: ONCO-LIQ – Cancer detection through routine blood testing TELEXOS – Improved cancer diagnostics through detection of circulating tumor cells in blood...

Recent Posts

  • The Game of Medical Breakthroughs (and Their Funding)
  • Thanksgiving 2021
  • Saving Second Base: Recapping Our Second Innovators
  • Save Second Base, The Innovators: Onco-liq
  • Save Second Base, The Innovators: Telexos GmbH

Recent Comments

  • Monica Janovitz on Save Second Base, The Innovators: Onco-liq
  • Janvi on Save Second Base, The Innovators: Onco-liq
  • Mercedes Lopez on Save Second Base, The Innovators: Onco-liq
  • CAROLA ZELALIA on Save Second Base, The Innovators: Onco-liq
  • Adriana on Save Second Base, The Innovators: Onco-liq

Archives

  • February 2022
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • May 2020

Categories

  • Access to Care
  • Breast Cancer
  • CANCER FUND
  • Care
  • Contributors
  • Innovators
  • My Lowdown
  • Personal Journeys
  • Race For A Cure Stalled?
  • The Bitch is Back
  • The Lowdown on Lowdown
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • Follow
  • Follow

Terms Of ServicePrivacy PolicyContact Us

© 2020 – 2023 CANCER FUND. All rights reserved

*DISCLAIMER: Our visitors acknowledge that: (1) this website includes information from four separate companies: CANCER FUND (a DBA of CXO Advisors & Management, LLC), Cancer Fund I, LLC, CF1 Reglagene Partners, LLC., and BioAccel; (2) CANCER FUND is not now by this website and the information shown herein offering any securities, nor soliciting an offer to buy any securities; (3) this website and the information herein shall not be construed as any description of the business of CANCER FUND in conjunction with any offering of securities; (4) the information contained on this website is subject to change without notice, and no one shall assume from the availability of this website and the information herein that the affairs of CANCER FUND have not changed since the date of this information; (5) Cancer Fund I, LLC and CF1 Reglagene Partners, LLC offer their investments through Funds411.com a “funding portal” as defined in section 3(a)(80) of the Securities Exchange Act of 1934 and under Rule 506(c) issued by the Securities and Exchange Commission (SEC) and those investments are offered to accredited investors only; (6) CANCER FUND is neither soliciting nor collecting donations and any charitable contributions made are made through BioAccel, a tax-exempt entity under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302 whose mission is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support; information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210; contributions to BioAccel to help meet its mission may be deductible to the extent permitted by federal law and donations solicited and accepted by BioAccel are limited to Arizona, Idaho, Indiana, Montana, Nebraska, South Dakota, Vermont, Wyoming, and Puerto Rico.

*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.

*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.

*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.

*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.

*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.

*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.